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Abstract
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Chronic pain states have resulted in an over-reliance on opioid pain relievers, which can carry
significant risks when used long-term. As such, alternative pain treatments are increasingly
desired. Although emerging research suggests that cannabinoids have therapeutic potential
regarding pain, results from studies across pain populations have been inconsistent. To provide
meta-analytic clarification regarding cannabis’s impact on subjective pain, we identified studies
that assessed drug-induced pain modulations under cannabinoid and corresponding placebo
conditions. A literature search yielded 25 peer-reviewed records that underwent data extraction.
Baseline and end-point data were used to compute standardized effect size estimates (Cohen’s d)
across cannabinoid administrations (k = 39) and placebo administrations (k = 26). Standardized
effects were inverse-variance weighted and pooled across studies for meta-analytic comparison.
Results revealed that cannabinoid administration produced a medium-to-large effect across
included studies, Cohen’s d = −0.58, 95% CI (−0.74, −0.43), while placebo administration
produced a small-to-medium effect, Cohen’s d = −0.39, 95% CI (−0.52, −0.26). Meta-regression
revealed that cannabinoids, β = −0.43, 95% CI (−0.62, −0.24), p < 0.05, synthetic cannabinoids, β
= −0.39, 95% CI (−0.65, −0.14), p < 0.05, and sample size, β = 0.01, 95% CI (0.00, 0.01), p <
0.05, were associated with marked pain reduction. These outcomes suggest that cannabinoid-based
pharmacotherapies may serve as effective replacement/adjunctive options regarding pain, however,
additional research is warranted. Additionally, given demonstrated neurocognitive side-effects
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associated with some constituent cannabinoids (i.e., THC), subsequent work may consider
developing novel therapeutic agents that capitalize on cannabis’s analgesic properties without
producing adverse effects.
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Chronic pain is an ever-growing concern in the United States. There is a rising economic
burden – currently estimated to be between $560 billion and $635 billion annually – that
stems from pain-related costs to patients, patient-care providers, healthcare systems, and
poor treatment outcomes among clinical pain populations (e.g., chronic lower back pain,
neuropathic pain, and fibromyalgia) (Henschke, Kamper, & Maher, 2015). These, and other,
conditions have resulted in an over-reliance on opioid-based pharmacotherapies. Although
some patients are appropriate for focused treatments involving opioids (e.g., acute pain),
patients with more chronic conditions (e.g., cancer) can achieve better outcomes by
managing pain through more comprehensive approaches (Chou et al., 2009). Thus, it has
become increasingly important to explore additional therapeutic opportunities. In recent
decades, cannabinoids – such as molecular compounds found in cannabis, including delta-9tetrahydrocannabinol (THC) and cannabidiol (CBD) – have been considered viable
treatment options regarding pain (Savage et al., 2016). As recently as 2018, 30 states had
enacted policies that permit cannabis use to treat various medical conditions, with 27 states
citing pain-related conditions as inclusionary criteria. Despite growing access to medicinal
cannabis, mixed (and on occasion, null) effects have been reported, underscoring the need to
expand research efforts regarding cannabinoid-induced pain mitigation.

Author Manuscript
Author Manuscript

Recently, several reports have examined cannabinoid administration effects on subjective
reports of pain (Hill, Palastro, Johnson, & Ditre, 2017). However, these accounts have
produced variant, and sometimes contradictory, conclusions. In one example, Johnson and
colleagues (2010) examined the impact of nabiximols (Sativex®), a standardized wholeplant cannabis extract oromucosal spray, on cancer-related pain. In that double-blind,
randomized controled trial (RCT), patients with intractable cancer pain entered a two-week
administration regimen and received THC:CBD extract (2.7 mg THC and 2.5 mg CBD),
THC extract (2.7 mg THC), or placebo. Patients were free to titrate their dosage as needed.
Following the drug administration regimen, Johnson et al. observed significant reductions in
subjective pain ratings among patients receiving THC:CBD extract compared to patients
receiving placebo. THC alone was less effective. In a similar example, Portenoy and
colleagues (2012) evaluated nabiximols as an add-on therapy for advanced cancer patients
with opioid-refractory (unresponsive) pain. Patients were placed into low-, medium-, or
high-administration conditions and pain was measured following a five-week intervention
interval. At the end of treatment, Portenoy et al. found that THC:CBD extract was associated
with greater pain reduction in the low-administration condition (1–4 sprays/day), but not in
the medium-administration (6–10 sprays/day) or high-administration conditions (11–16
sprays/day). Taken together, these outcomes suggest that cannabinoids may represent
potential pharmacological tools for pain reduction. On the other hand, several studies have
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shown no difference between cannabinoids and corresponding placebo administrations. For
example, Lichtman and colleagues (2018) leveraged a double-blind RCT to examine pain
outcomes among cancer patients with uncontrolled pain following a two-week nabiximols
administration period. Following the intervention, Lichtman et al. compared pain
modulations from baseline between cannabinoid and placebo conditions, revealing no
superior effects associated with THC:CBD extract. Moving forward, an important challenge
facing biomedical research involves coalescing results from studies involving various pain
populations receiving cannabinoid administrations to determine overall therapeutic potential.

Author Manuscript
Author Manuscript
Author Manuscript

Towards this goal, several systematic reviews have endeavored to summarize cannabis’s
putative pain-related therapeutic effects (Abrams, 2018; Campbell et al., 2001; Colombo,
Annovazzi, & Comi, 2006; Deshpande, Mailis-Gagnon, Zoheiry, & Lakha, 2015; Lynch &
Campbell, 2011; Lynch & Ware, 2015; Sznitman & Zolotov, 2015; Wright, 2007). These
reviews have provided competing conclusions. In one review, Campbell and colleagues
(2001) considered outcomes from nine randomized active- and placebo-controlled trials
involving cannabinoids (five trials involved cancer-related pain, two involved chronic pain,
and two acute post-operative pain), with a focus on pain intenseness scores, pain relief
scores, and adverse effects. Those authors concluded that the cannabinoids considered were
no more effective than active control conditions, including the opioid analgesic codeine,
stressing that cannabinoid administration to treat post-operative pain would be
“undesirable,” given unwanted central nervous system depressant effects. However, opioids
have also been linked with depressant/sedative effects (Chou et al., 2009). Moreover, other –
perhaps more severe – opioid-related adverse effects include respiratory depression,
especially when paired with other substances, such as benzodiazepines and alcohol (Chou et
al., 2009). Given the abuse potential associated with opioids, these (and other) side-effects
underscore the need to consider replacement and/or adjunctive pain management
approaches. Additionally, Campbell et al. noted that, among RCTs considered in the
systematic review, none had examined active cannabis. That is, the trials examined pain
reduction associated with THC, nitrogen-containing benzopyran derivative,
benzopyranoperidine, or levonantradol. Importantly, cannabinoid-induced analgesia may
stem from compound or synergistic effects associated with several cannabinoids. For
example, preclinical evidence suggests that high-dose CBD modulates antinociceptive
effects associated with low-dose THC, indicating that both cannabinoids may be involved in
pain reduction (Varvel et al., 2006). Furthermore, work from Comelli and colleagues
(Comelli, Giagnoni, Bettoni, Colleoni, & Costa, 2008) demonstrates that whole-plant
cannabis extract provides improved nociceptive efficacy compared to corresponding doses of
constituent cannabinoids. As such, as the corpus of cannabis-related pain investigations
continues growing, it is possible that more comprehensive assessments could reach
alternative conclusions regarding cannabinoid analgesia. In a more recent review, The
National Academies of Sciences, Engineering and Medicine considered more than 10,000
peer-reviewed abstracts to characterize cannabis’s potential therapeutic utility across several
domains, including pain. That committee concluded that “there was conclusive or substantial
evidence that Cannabis or cannabinoids are effective for the treatment of pain in adults,”
(Abrams, 2018). However, narrative and systematic reviews often omit representative
estimates of effect magnitude and therefore cannot provide quantitative conclusions about
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outcomes of interest. As such, objective techniques that determine statistical convergence
across published studies involving cannabinoid-induced pain reduction are needed to more
accurately characterize potential therapeutic effects.
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Meta-analyses present powerful opportunities to coalesce conventional effect size estimates
(e.g., Cohen’s d) across published studies, providing clarification regarding results and
permitting assessments not possible within the original, single report. Within this
framework, several study-level effect size estimates derived under comparable experimental
conditions are averaged, producing one pooled (representative) effect size estimate (Hedges
& Olkin, 1985). Regarding pharmacologic manipulations, pooled effect sizes are used to
characterize cross-study drug administration effects on specific end-points (Wilkinson et al.,
2018), or to make comparisons between two (or more) drug administration conditions
(Bushe et al., 2016). Towards this goal, several meta-analyses have provided some insight
into cannabinoid-related pain reduction (Andreae et al., 2015; Aviram & Samuelly-Leichtag,
2017; De Vita, Moskal, Maisto, & Ansell, 2018; Goldenberg, Reid, IsHak, & Danovitch,
2017; Iskedjian, Bereza, Gordon, Piwko, & Einarson, 2007; Martin-Sanchez, Furukawa,
Taylor, & Martin, 2009; Phillips, Cherry, Cox, Marshall, & Rice, 2010; Whiting et al.,
2015). For example, Iskedjian and colleagues (2007) synthesized results from six studies
examining cannabinoid administration within the limited context of multiple sclerosis (MS).
When considering baseline versus end-point pain ratings among 298 patients, Iskedjian et al.
observed that cannabinoids were associated with greater pain reduction relative to placebo.
However, whether these effects extend beyond MS-related pain (e.g., neuropathic pain)
remained unclear. In a more comprehensive meta-analysis, Aviram and Samuelly-Leichtag
(2017) examined pain reduction associated with cannabinoid-based medicines across 24
RCTs. Those researchers considered several pain populations, including neuropathic pain,
cancer-related pain, non-cancer pain, and post-operative pain, as well as active-control and
placebo-control designs. Overall, Aviram and Samuelly-Leichtag reported “limited” support
for cannabinoid-based medicines across considered RCTs. However, a more focused
assessment that excluded active-control designs – which were believed to have increased
analgesic efficacy compared to placebo – demonstrated improved analgesic outcomes
associated with cannabinoid-based medicines. Surprisingly, the extent to which specific
study-level characteristics, such as sample size, age, and sex composition (sex ratio), may
modulate observed pain outcomes remains to be meta-analytically explored. Indeed, these
active research areas have received considerable attention in recent years (Lauer, 2016).
Here, we address this open-ended question using meta-regression to examine cannabinoidand placebo-related pain reduction with respect to several study-level characteristics (Baker
et al., 2009).

Author Manuscript

To determine cross-study cannabinoid-related standardized effect sizes regarding selfreported pain reduction, and to examine potential associations with important study-level
characteristics, we leveraged a combined meta-analysis and meta-regression approach. In a
primary assessment, we used meta-analysis techniques to coalesce drug-induced pain
reduction standardized effect sizes associated with cannabinoid and placebo administrations
to produce pooled effects and enable statistical comparison. In a second assessment (Glass,
Smith, & McGaw, 1981), we used meta-regression to examine relationships between various
continuous and categorical explanatory variables and drug-induced pain reduction effect
Exp Clin Psychopharmacol. Author manuscript; available in PMC 2019 August 01.
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sizes. Specifically, we used multiple linear regression to examine relationships between
several study-level characteristics (sample size, age, sex composition, experimental design,
and pain population) and drug administration conditions. Overall, we posited that
cannabinoid administration would be associated with pain reduction across included studies,
and that placebo administration would be less effective. Furthermore, we expected that
study-level characteristics would be associated with pain reduction standardized effect sizes.
Providing clarification about potential pain-mitigating effects associated with cannabinoids
should enable enhanced scientific understanding about possible therapeutic applications.

Methods
Search

Author Manuscript

We conducted a literature search to identify pharmacological manipulation studies that
assessed cannabinoid-induced alterations in subjective pain ratings. Primary searches were
carried out using PudMed (www.ncbi.nlm.nih.gov/pumed/) and Web of Science (http://
webofknowledge.com) with the search terms: cannabis OR cannabinoids OR delta-9tetrahydrocannabinol OR THC OR cannabidiol OR CBD OR marijuana OR nabilone OR
dronabinol OR nabiximols AND pain OR noxious OR analgesia OR visual analog scale OR
VAS OR numeric rating scale OR NRS. We further reviewed the reference sections of each
record identified during the exhaustive search, in particular, systematic and narrative review
papers (Campbell et al., 2001; Colombo et al., 2006; Deshpande et al., 2015; Lynch &
Campbell, 2011; Lynch & Ware, 2015; Sznitman & Zolotov, 2015; Wright, 2007) and
existing meta-analyses (Andreae et al., 2015; Aviram & Samuelly-Leichtag, 2017; De Vita
et al., 2018; Goldenberg et al., 2017; Iskedjian et al., 2007; Martin-Sanchez et al., 2009;
Phillips et al., 2010)

Author Manuscript

Screen

Author Manuscript

During screening, record abstracts were inspected to determine appropriateness. Specifically,
records that did not represent peer-reviewed original research studies were removed from the
meta-analysis review pipeline (e.g., letters to editors, reviews, conference proceedings).
Records involving non-human models were also not considered. This meta-analysis was
restricted to RCTs that: (A) assessed drug-induced pain reductions following cannabinoid
administration across studies, including whole-plant cannabis, whole-plant cannabis
extracts, and synthetic cannabinoids (i.e., Dronabinol, Nabilone, CT3), and corresponding
active or placebo administrations, (B) described pain reductions as differences between
baseline (pre-administration) and end-point (post-administration) measurements, and (C)
used a parallel-groups (i.e., independent samples) or crossover (i.e., repeated measures)
design to examine pain reductions. Importantly, although active control studies were
considered in the current meta-analysis (Frank, Serpell, Hughes, Matthews, & Kapur, 2008;
Pini et al., 2012), drug-induced pain reductions associated with active control administration
(e.g., ibuprofen) were not included in placebo sub-group analyses. The current meta-analysis
reflects papers published through August 2018.
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Remaining records were obtained as complete published articles and assessed by two
reviewers (J.A.Y and Z.E.M). Reviewers cross-checked extracted data points and resolved
disagreement before commencing meta-analyses. Extracted data points included: author,
publication year, sample size(s), pharmacological manipulation(s) (whole-plant cannabis,
whole-plant cannabis extract, synthetic cannabinoid, and placebo), pain population (pain
linked with various medical conditions), baseline mean pain score, end-point mean pain
score, and associated variance estimates. Studies that involved more than two (ki)
administration conditions (e.g., THC:CBD extract, THC extract, and placebo) contributed ki
(k = 3) mean gain standardized effect sizes to quantitative assessment, where k describes
total standardized effect sizes considered in the current meta-analysis. Because we sought to
pool cannabinoid-related standardized effect sizes across included studies, and because we
sought to pool placebo-related standardized effect sizes across included studies, baseline and
end-point pain severity scores were extracted from cannabinoid and placebo conditions
separately. Studies that omitted baseline and/or end-point pain severity scores were
excluded. When required, pain severity scores were computed using available summary data
(e.g., mean pain percent reduction (Abrams et al., 2007; Johnson et al., 2010; Langford et
al., 2013; Narang et al., 2008; Skrabek, Galimova, Ethans, & Perry, 2008). Data points
collected from one record required reverse scoring (Wade, Robson, House, Makela, & Aram,
2003). Although baseline and end-point pain severity scores were necessary for inclusion,
several records omitted associated variance estimates (Abrams et al., 2007; Blake, Robson,
Ho, Jubb, & McCabe, 2006; Buggy et al., 2003; Chou et al., 2009; Corey-Bloom et al.,
2012; Johnson et al., 2010; Karst et al., 2003; Langford et al., 2013; Narang et al., 2008;
Nurmikko et al., 2007; Portenoy et al., 2012; Rog, Nurmikko, Friede, & Young, 2005;
Skrabek et al., 2008; Svendsen, Jensen, & Bach, 2004; Wilsey et al., 2008). In such cases,
we employed several strategies to secure missing variance data. First, we contacted the lead
and/or corresponding authors with data requests. Second, to supplement remaining records,
we leveraged the freely available service WebPlotDigitizer (https://automeris.io/
WebPlotDigitizer) to compute variance estimates using manuscript figures – an accepted
technique to extract numeral data from data visualizations (Rohatgi, 2018). Third, when data
requests and data extraction from visualizations were not possible, missing variance
estimates were reconciled via mean imputation using assembled variance estimates (Cooper,
Hedges, & Valentine, 2009). Notably, imputed variance estimates represented approximately
35% (46/130) of total variance data. Outcome measures included quantitative pain-rating
scales, such as numeric rating scales (NRS) (Hartrick, Kovan, & Shapiro, 2003) and visual
analog scales (VAS) (Ferraz et al., 1990). Quantitative pain-rating scales involve asking
participants to describe pain severity, routinely anchored by zero, indicating “no pain,” and
10, indicating “worst pain.” Results from studies using 100-point ranges were scaled to
enable pooling and comparison.
Following data extraction, baseline pain severity scores, end-point pain severity scores, and
associated variance estimates, were used to compute study-level standardized mean gain
effect size (i.e., Cohen’s d) (Becker, 1988). Standardized effect sizes were used to calculate
associated standard errors (Lipsey & Wilson, 2001) and confidence intervals (Nakagawa &
Cuthill, 2007). To facilitate meta-analytic comparison, study-level standardized effect sizes
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were then inverse-variance weighted and pooled to produce an average cannabinoid-induced
effect and an average placebo-induced effect (Hedges & Olkin, 1985). Monte Carlo
simulations suggest that inverse-variance weighting produces optimal pooled effect sizes in
meta-analysis assessments (Sánchez-Meca & Marin-Martinez, 1998). Forest plots were
created to visualize standardized effect sizes. We assessed the degree to which variation
among cannabinoid and placebo administrations was attributed to chance via the I2 statistic
and associated confidence intervals (Higgins & Thompson, 2002; Higgins, Thompson,
Deeks, & Altman, 2003). Pooled effects were compared with an independent-samples mean
difference test (Hedges & Olkin, 1985; Hedges & Pigott, 2001).
Multiple Linear Regression (Meta-Regression)

Author Manuscript

Meta-regression examines the relationships between continuous and/or categorical
explanatory variables (e.g., sample size, sample age, sample sex composition) and a
continuous outcome variable (e.g., study-level standardized effect sizes) (Green & Higgins,
2005). Specifically, we used an exploratory fixed-effects multiple linear regression (metaregression) approach (Greenland, 1987; Luebke & Brunkwall, 2015), to explore
relationships between pain reduction effects and: drug administration condition [placebo,
cannabinoid (whole-plant, whole-plant extract), synthetic cannabinoid (Dronabinol,
Nabilone, CT3)], sample size (reported sample size), sample age (mean sample age), sample
sex composition (sample sex ratio), experimental design (parallel versus crossover), and pain
population (abdominal pain, arthritis, cancer, chronic pain, diabetes, fibromyalgia, headache,
human immunodeficiency virus (HIV), multiple sclerosis, neuropathic pain, post-operative
pain, and “various,” or mixed pain populations within one effect). Data were examined using
statistical assumptions associated with regression, including normality, residual normality,
and equal variances. Outliers among standardized effect sizes [i.e., median effect +/−
interquartile range (IQR) × 1.5] were adjusted using upper/lower quartile replacement
(Tukey, 1977). Categorical variables (e.g., placebo, cannabinoid, synthetic cannabinoid)
were dummy coded to facilitate meta-regression assessment (Wolf & Cartwright, 1974).

Author Manuscript

Ethics and Open Science Practices
As is common with meta-analytic assessments, the current report did not involve human
subjects and therefore did not require institutional review board approval (Sullivan, 2011). In
line with current recommendations and open science best practices (Open Science, 2015),
we have made meta-data and corresponding code associated with this work freely available
on GitHub (https://doi.org/10.5281/zenodo.1463262).

Results
Author Manuscript

Primary Meta-Analysis
Literature search and review results are depicted in Table 1 and Figure 1. The search
produced 954 records which underwent screening. Using exclusion criteria described above,
899 records were removed during abstract review, and another 30 were removed during fulltext review. The current meta-analysis included data from 25 records that met inclusion
criteria, providing data from k = 65 individual pharmacologic manipulations (39
cannabinoid manipulations versus 26 placebo manipulations), involving 2,248 participants.
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On average, studies reported that participants’ mean age ranged from 43.50 to 62.80 years
(mean = 52.09). Included studies assessed drug-induced pain reductions associated with
several cannabinoid administration conditions, including whole-plant cannabis (n = 5),
whole-plant cannabis extract (n = 11), and synthetic cannabinoids (n = 9). Pain-related
clinical samples (pain populations) considered were neuropathic pain (n = 7), cancer (n = 4)
diabetes (n = 3), MS (n = 3), abdominal pain (n = 1), arthritis (n = 1), chronic pain (n = 1),
fibromyalgia (n = 1), headache (n = 1), HIV (n = 1), post-operative pain (n = 1), and
“various” (n = 1). Standardized effect sizes are organized according to pain population in
Supplemental Figure 1. On average, studies reported that 51.57% of participants were
women. Fifteen studies provided data from parallel-group designs and 10 provided data
from crossover designs.

Author Manuscript

Inverse-variance weighting and pooling across cannabinoid standardized effect sizes
revealed that cannabinoid administration was associated with a ‘medium-to-large’ effect,
Cohen’s d = −0.58, 95% CI (−0.74, −0.43) (Figure 2). An assessment of variation revealed
considerable heterogeneity among cannabinoid effect sizes, I2 = 91.47%, 95% CI (87.93%,
92.37%). On the other hand, inverse-variance weighting and pooling across placebo
standardized effect sizes revealed that placebo administration was associated with a ‘smallto-medium’ effect, Cohen’s d = −0.39, 95% CI (−0.52, −0.26) (Figure 3). An assessment of
variation revealed considerable heterogeneity among placebo effect sizes, I2 = 92.66%, 95%
CI (89.18%, 93.70%). Overall, cannabinoid administration was associated with greater pain
reduction compared to placebo administration, t (64) = −4.06, p < 0.05. Visual inspection
revealed some overlap between drug administration condition confidence intervals.
Exploratory Multiple Linear Regression (Meta-Regression)

Author Manuscript
Author Manuscript

Overall, the meta-regression model explained a moderate proportion of variance among
individual studies, R2 = 0.37 (adjusted R2 = 0.30), F (6,48) = 4.62, p < 0.05. Reported pvalues are associated with corresponding coefficient hypotheses tests. Meta-regression
results revealed that, when controlling for other explanatory variables, drug administration
conditions were linked with pain reduction among included studies, such that cannabinoids
(whole-plant cannabis and whole-cannabis extracts) β = −0.43, 95% CI (−0.62, −0.24), p <
0.05 (Figure 4), and synthetic cannabinoids (Dronabinol, Nabilone, and CT3) β = −0.39,
95% CI (−0.65, −0.14), p < 0.05 (Figure 4), performed better than placebo. Furthermore,
meta-regression results showed that, when controlling for other explanatory variables,
sample size was linked with pain reduction, β = 0.01, 95% CI (0.00, 0.01), p < 0.05, such
that studies involving smaller samples tended to report greater pain reduction effects (Figure
4). There were no observed interactions between drug administration conditions and sample
size. Finally, meta-regression results showed that, when controlling for other explanatory
variables, sample sex composition was linked with a modest, however non-significant,
effect, β = −0.64, 95% CI (−1.37, 0.09), p = 0.09, such that studies including more female
participants tended to report greater pain reductions (Figure 5).
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Discussion
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In this meta-analytic study, we coalesced results from peer-reviewed primary research
articles that characterized cannabinoid- and placebo-induced reductions of subjective pain
ratings across medical conditions. Our findings extend current understanding about
cannabinoids and pain, taking a meta-regression approach to examine relationships between
various study-level characteristics and drug-induced pain reductions. When considering
reductions in self-reported pain, we observed that cannabinoid administration was associated
with a ‘medium-to-large’ (Cohen, 1988) pooled effect size across included studies.
Importantly, cannabinoid administration was associated with statistically significant greater
pain reduction than placebo administration, which yielded a ‘small-to-medium’ (Cohen,
1988) pooled effect size. Indeed, placebo administration has been shown to enhance
expectations about pain reduction (Bushe et al., 2016), potentially assuaging negative
emotional/motivational aspects about pain experiences. Finally, results from our metaregression analysis suggested that, when controlling for other explanatory variables, drug
administration conditions and sample size predicted observed pain reduction. Taken
together, these meta-analytic outcomes provide some evidence that cannabinoids, relative to
placebo, might mitigate subjective pain reporting among those experiencing chronic pain
tied to various medical conditions. However, more research is needed to understand nuances
in cannabinoid-induced pain reduction, including outcome differences between single-dose
versus long-term cannabinoid treatments, complex interactions with concurrent analgesic
pharmacotherapies, and changes in cannabis conditional dependence rates as a function of
increased access.
Neuropsychological Impact of Cannabinoid-Based Administrations

Author Manuscript

When considering cannabis’s effect on pain, our primary meta-analysis outcomes suggest
that cannabinoids may represent a viable option regarding pain management and treatmentoutperforming corresponding placebo conditions across included studies. That cannabinoids
were associated with pain reduction is not surprising, given that the most common medicinal
cannabis applications throughout documented human history involve administration for pain
(Parker, 2017). Indeed, early evidence suggests that medicinal cannabis may have been used
to relieve pain around 400 CE (Zlas et al., 1993). However, it was just in the 1990s that
several reports described an endogenous cannabinoid framework embedded within the
central nervous system (Devane et al., 1992) and peripheral nervous system (Munro,
Thomas, & Abu-Shaar, 1993), which interacts with exogenous cannabinoids to modulate
pain.

Author Manuscript

Processing pain signals starts with nociceptive sensation signal transduction throughout the
peripheral nervous system and terminates with subjective pain perception within the central
nervous system (for an exteded review, see Millan, 1999). First, peripheral sensory neurons
detect noxious stimulation, which is then communicated to neuronal bodies around the
spinal column. Next, sensory neurons synapse onto central dorsal horn neurons within the
spinal cord, where pain signals are integrated across pathways. Finally, central dorsal horn
neurons forward pain signals via ascending pathways to the brainstem, thalamus, and
cortical brain regions, which process higher-order pain behavior. Notably, cannabinoid
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receptors are densely concentrated in the frontal and limbic cortices- brain regions also
associated with processing pain, including the anterior cingulate cortex (ACC) (Glass, Faull,
& Dragunow, 1997). As such, cannabinoid receptor agonists may work to mitigate
subjective pain experiences via interactions with brain regions responsible for processing
more complex mental operations, such as pain-related affective and motivational
dimensions. Consistent with such an interpretation, recent reports have examined the
relationship between cannabis and pain-related brain function. For example, Lee and
colleagues (2013) used functional magnetic resonance imaging (fMRI) to investigate
cannabis’s impact on blood-oxygen-level dependent (BOLD) signal fluctuations in response
to experimental chemical pain (i.e., capsaicin) among normal participants. Those researchers
observed that, when compared to placebo, cannabinoid administration (i.e., 15 mg THC)
reduced pain unpleasantness, but not pain intenseness. That is, cannabinoid administration
may modulate pain perception (unpleasantness) without affecting pain sensation
(intenseness), a position supported by a recent meta-analysis of cannabinoid-induced
modulations in experimental pain (De Vita et al., 2018). Moreover, cannabinoid-induced
reductions in pain unpleasantness correlated with less ACC activation. Indeed, ACC
functioning has been implicated in various affective-motivational components in higherorder pain processing, such as conditioned place avoidance (Johansen, Fields, & Manning,
2001; LaGraize, Labuda, Rutledge, Jackson, & Fuchs, 2004), perceived threat from noxious
stimulation (Foltz & White Jr, 1962), and monitoring survival-relevant goals (Lieberman &
Eisenberger, 2015). Although acute cannabinoid receptor agonism dampens ACC
responding to pain, effectively reducing pain-related negative affect, whether these effects
endure beyond acute administration remains unclear. In a recent neuroimaging metaanalysis, Yanes and colleagues (2018) examined neurofunctional alterations associated with
chronic cannabis use. When considering cannabis’s impact across various mental tasks,
those researchers observed that chronic cannabis was linked with, among other changes,
decreased ACC activation. Furthermore, ancillary assessments revealed that activity within
the ACC has been consistently linked with pain-related taxonomic descriptors (i.e., Pain,
Pain Monitor/Discrimination) across the functional neuroimaging literature. To summarize,
the neurobiological outcomes discussed here may represent potential higher-order, brainlevel mechanisms that support demonstrated cannabis-induced pain reduction.
Outcomes from Meta-Regression

Author Manuscript

Meta-regression results showed that sample size was associated with pain reduction
standardized effect sizes across studies, such that studies involving smaller samples reported
greater pain reduction. Moreover, there was no interaction between reported sample size and
drug administration conditions (i.e., cannabinoid, synthetic cannabinoid, and placebo),
suggesting that this was the case across pharmacologic manipulations considered. Sample
size represents an important determinant regarding how generalizable research results are to
target populations (Wiedermann & Wiedermann, 2015). Often, studies with smaller samples
have reported better therapeutic outcomes (Sterne & Egger, 2001). This phenomenon has
been linked to outcome reporting biases (Chan & Altman, 2005), such as data omission
when results lack statistical significance, poorer methodological parameters (Kjaergard,
Villumsen, & Gluud, 2001), and increased between-study heterogeneity among studies with
small samples (IntHout, Ioannidis, Borm, & Goeman, 2015). Moving forward, it is
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important that researchers, healthcare providers, and law makers consider outcomes from
studies on cannabinoid-induced pain reductions within the context of the sample sizes that
derived them.

Author Manuscript

When considering sex-dependent effects in cannabinoid-induced pain reduction, metaregression results suggested that among included studies, those studies that recruited more
female participants reported greater, although non-significant, standardized effect sizes
across drug administration conditions. It is worth noting that meta-regression outcomes
derived using summary statistics (e.g., sample sex composition) may exhibit ecological
confounding (Morgenstern, 1982) compared to using patient-level data (Thompson &
Higgins, 2002). As such, the relationship between biological sex and cannabinoid analgesia
should become clearer as new studies emerge that provide within-sample comparisons.
Accumulating preclinical evidence suggests that females may be more sensitive to
cannabis’s pain-reducing effects. Indeed, greater pain reduction among females following
cannabinoid-receptor agonism has been shown in acute pain and non-acute pain animal
models (Craft, Marusich, & Wiley, 2013; Craft, Wakley, Tsutsui, & Laggart, 2012; Tseng &
Craft, 2001). However, whether these sex-dependent effects extend to humans remains
unclear. One recent report from Cooper and Haney (2016) examined pain reduction among
male and female cannabis users following active cannabis consumption (3.65–5.60% THC)
and placebo consumption (0.00% THC). Among male cannabis users, those researchers
found that cannabis consumption increased pain-onset latency compared to placebopresumably by reducing pain sensitivity. Among female cannabis users, however, no
differences were observed between active cannabis and placebo conditions. These discordant
outcomes may highlight important nuances about cannabinoid-related reductions in reported
pain. Specifically, findings from the current meta-analysis represent data from participants
with various clinical conditions. Growing evidence suggests that women experience greater
clinical pain (Rosseland & Stubhaug, 2004; Unruh, 1996), often endorsing increased painrelated distress (Paller, Campbell, Edwards, & Dobs, 2009). It is then possible that reported
sex-differences in cannabinoid-induced pain reduction stem from differences in pain
reporting- not pain sensation and/or perception. With this in mind, one important question
facing subsequent research involves our current understanding of sex-dependent effects in
cannabinoid-induced pain reduction. Moreover, subsequent research may consider sex
differences across complimentary pain outcomes, such as pain tolerance, pain ratings, and
pain questionnaires/scales.

Author Manuscript
Limitations

Author Manuscript

Findings presented here should be considered in the context of several methodological
limitations. First, as is common with meta-analyses, our outcomes and associated
interpretations are constrained by the state of the current literature. Accordingly, results
obtained here should be considered preliminary given the modest sample size (i.e., 25
papers). Moreover, recommendations regarding sub-group analyses and meta-analytic
modeling prevented more refined assessments, such as estimating standardized effect sizes
as a function of cannabinoid sub-classifications (e.g., whole-plant cannabis, whole-plant
cannabis extract, synthetic cannabinoid, THC, CBD, THC/CBD), dose (e.g., 2.5mg THC,
5mg THC), administration route (e.g., smoke, oromucosal spray, capsule), and pain
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population (e.g., central/peripheral neuropathic pain, cancer pain, multiple sclerosis pain)
(Green & Higgins, 2005). The inclusion of studies that involved several drug conditions and
clinical samples into the same meta-analysis presumably contributed to observed betweenstudy heterogeneity. More granular meta-analytic approaches should become possible as
additional relevant studies are made available. Second, even though included studies
involved comparable end-point measures (i.e., numeric rating scale, visual analog scale),
these studies may contain confounds and/or biases that have not been addressed, such as
temporal variation in societal attitudes towards cannabis, regional policies that promote
medicinal cannabis, and inter-individual differences regarding cannabis’s expected
effectiveness. With this in mind, we used fixed-effects multiple linear regression (metaregression) to control confounding effects where possible (e.g., experimental design)
(Stanley & Jarrell, 1989). Also, moving forward, researchers may consider systematically
collecting/reporting concomitant end-point measures [e.g., McGill Pain Questionnaire
(Melzack, 1975)], to provide more complete characterizations of cannabis-related analgesic
effects. Third, despite rigorous review methods, several records were excluded from the
current meta-analysis due to missing data. According to the Open Science Collaboration
(2015), problematic practices within psychological science include selective reporting,
omitting analyses, and insufficient specification regarding experimental parameters.
Moreover, the current meta-analysis cannot consider studies that were conducted but never
reported (i.e., “the file drawer problem”) (Rosenthal, 1979). Thus, improved reporting
practices should enable enhanced meta-analysis assessments in general, and regarding
cannabinoids in particular. Finally, despite showing that cannabinoid administration was
associated with pain reduction, many studies included in this meta-analysis did not give full
consideration to neurocognitive side-effects linked with cannabis (for an extended review,
see Crane, Schuster, Fusar-Poli, & Gonzalez, 2013). Future investigations should
systematically examine cannabis’s therapeutic properties in the context of co-occurring
undesired neurocognitive effects.

Author Manuscript
Author Manuscript

Conclusions

Author Manuscript

Our meta-analysis outcomes show that cannabinoid administration was associated with
reductions in subjective pain across included studies, making them viable candidates for
pain management and treatment. Moreover, meta-regression results suggested that drug
administration condition and sample size predicted pain reduction effects. Finally, we
observed that sample sex composition was associated (although, not statistically significant)
with observed pain reduction, suggesting that this may be an important biological variable
when considering cannabis-induced pain reduction. As social, societal, and political attitudes
towards cannabis evolve, it is becoming increasingly important to provide enhanced
scientific understanding regarding risks and potential therapeutic applications. Such
understanding should lead to more informed decision-making regarding cannabis among
patients, care providers, and law makers.
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Public Significance Statement
Chronic pain states are an ever-growing concern in the United States, costing an
estimated $600 billion annually in lost labor and healthcare expenses. These, and other,
conditions have resulted in an over-reliance on opioid-based pharmacotherapies. Results
from the current meta-analysis provide some support that cannabinoids might mitigate
subjective pain among patients with pain-related clinical conditions.
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Figure 1. Literature Search and Review Pipeline.

Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) pipeline
diagram showing search and review results. A preliminary search produced 949 records,
with an additional 5 assembled from additional resources (e.g., narrative reviews), totaling
954 records overall. During abstract review, 899 records were removed from the metaanalysis pipeline. During complete manuscript review, an additional 30 records were
discarded based on study exclusion criteria. Finally, the 25 remaining records underwent
data extraction and subsequent meta-analytic assessment.
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Figure 2. Pooled Cannabinoid Administration Effect.
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Study-level standardized effect size estimates (Cohen’s d) were computed for each
cannabinoid administration across included studies. Circle sizes are proportional to small,
medium, and large effect size estimate interpretations (Cohen, 1988). Study-level estimates
were inverse-variance weighted and pooled to determine a representative estimate. When
considering overall pain reduction effects, cannabinoid administration was associated with a
medium-to-large effect across studies, Cohen’s d = −0.58, 95% CI (−0.74, −0.43).
N, sample size; ES, standardized effect size estimate; CI, confidence interval.
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Figure 3. Pooled Placebo Administration Effect.
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Study-level standardized effect size estimates (Cohen’s d) were computed for each placebo
administration across included studies. Circle sizes are proportional to small, medium, and
large effect size estimate interpretations (Cohen, 1988). Study-level estimates were inversevariance weighted and pooled to determine a representative estimate. When considering
overall pain reduction effects, placebo administration was associated with a small-tomedium effect across studies, Cohen’s d = −0.39, 95% CI (−0.52, −0.26).
N, sample size; ES, standardized effect size estimate; CI, confidence interval.
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Figure 4. Bivariate Relationship Between Effect Size Estimates and Significant Predictors.

Meta-regression results revealed that, when controlling for other explanatory variables, drug
administration conditions were linked with pain reduction among included studies, such that
cannabinoids (whole-plant cannabis and whole-cannabis extracts) β = −0.43, 95% CI
(−0.62, −0.24), p < 0.05, and synthetic cannabinoids (Dronabinol, Nabilone, and CT3) β =
−0.39, 95% CI (−0.62, −0.24), p < 0.05, performed better than placebo. Furthermore, metaregression results showed that, when controlling for other explanatory variables, sample size
was linked with pain reduction, β = 0.01, 95% CI (0.00, 0.01), p < 0.05, such that studies
involving smaller samples tended to report greater pain reduction.
Cannabinoids = shaded (green) circles; placebo = unshaded circles.

Author Manuscript
Author Manuscript
Exp Clin Psychopharmacol. Author manuscript; available in PMC 2019 August 01.

Yanes et al.

Page 23

Author Manuscript
Author Manuscript
Author Manuscript

Figure 5. Bivariate Relationship Between Effect Size Estimates and Sample Sex Composition
(Sex Ratio).

Meta-regression results showed that, when controlling for other explanatory variables,
sample sex composition was linked with a modest, albeit non-significant, effect, β = −0.64,
95% CI (−1.37, 0.09), p = 0.09, such that studies including more female participants tended
to report greater pain reductions.
Cannabinoids = shaded (green) circles; placebo = unshaded circles.
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Table 1.

Studies Meeting Inclusion Criteria.

Author Manuscript

Numbering corresponds to studies meeting inclusion criteria. Extracted variables were administration
condition (administration), including cannabis whole plant, cannabis extract, synthetic cannabinoid, and
placebo, administration dose (dose), administration route (route), population with pain-related clinical
condition (pain population), subjective pain outcome measure (pain measure), and associated scale (scale).
THC, delta-9-tetrahydrocannabinol; CBD, cannabidiol. CT3, dimethylheptyl-delta-8-tetrahydrocannabinol-11oic acid; HIV, human immunodeficiency virus;
Details Regarding Sampled Studies
No.

Author

Year

1

Abrams et al.

2007

Whole Plant

3.56 % THC

Smoke

HIV

Visual Analog Scale

0 – 100

2

Blake et al.

2006

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Arthritis

Numeric Rating Scale

0 – 10

3

Buggy et al.

2003

Extract

5.0 mg THC

Capsule

Post-Operation

Visual Analog Scale

0 – 10

4

Corey-Bloom et al.

2012

Whole Plant

4.0% THC

Cigarette

Multiple Sclerosis

Visual Analog Scale

0 – 100

5

De Vries et al.

2017

Synthetic (Dronabinol;

8 mg

Tablet

Abdominal Pain

Visual Analog Scale

0 – 10

Administration

Dose

Route

Pain Population

Pain Measure

Scale

Author Manuscript
Author Manuscript

De Vries et al.

2017

Synthetic (Dronabinol)

8 mg

Tablet

Abdominal Pain

Visual Analog Scale

0 – 10

6

Fallon et al.

2017

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Capsule

Cancer

Numeric Rating Scale

0 – 10

7

Frank et al.

2008

Synthetic (Nabilone)

0.25 mg

Capsule

Neuropathic Pain

Visual Analog Scale

0 – 100

8

Johnson et al.

2010

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Capsule

Cancer

Numeric Rating Scale

0 – 10

Extract

2.7 mg THC

Capsule

Cancer

Numeric Rating Scale

0 – 10

9

Karst et al.

2003

Synthetic (CT-3)

10.0 mg

Capsule

Neuropathic Pain

Visual Analog Scale

0 – 100

10

Langford et al.

2012

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Neuropathic Pain

Numeric Rating Scale

0 – 10

11

Lichtman et al.

2017

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Cancer

Numeric Rating Scale

0 – 10

12

Narang et al.

2008

Synthetic (Dronabinol)

20.0 mg

Capsule

Chronic Pain

Numeric Rating Scale

0 – 10

2008

Synthetic (Dronabinol)

10.0 mg

Capsule

Chronic Pain

Numeric Rating Scale

0 – 10

Author Manuscript

13

Nurmikko et al.

2007

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Neuropathic Pain

Numeric Rating Scale

0 – 10

14

Pini et al.

2012

Synthetic (Nabilone)

0.5 mg

Capsule

Headache

Visual Analog Scale

0 – 10

15

Portenoy et al.

2012

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Cancer

Visual Analog Scale

0 – 10

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Cancer

Visual Analog Scale

0 – 10

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Cancer

Visual Analog Scale

0 – 10

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Neuropathic Pain

Numeric Rating Scale

0 – 10

16

Rog et al.

2007
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Details Regarding Sampled Studies

Author Manuscript

No.

Author

Year
Administration

Dose

Pain Population

Pain Measure

Scale

17

Schimrigk et al.

2017

Synthtic (Nabilone)

7.5 mg –
15.0 mg

Capsule

Multiple Sclerosis

Numeric Rating Scale

0 – 10

18

Selvarajah et al.

2010

Extract (Sativex)

2.7 mg
THC / 2.5
mg CBD

Oromucosal Spray

Diabetes

Visual Analog Scale

0 – 100

29

Skrabek et al.

2007

Synthetic (Nabilone)

0.5 mg

Capsule

Fibromyalgia

Visual Analog Scale

0 – 10

20

Svedson et al.

2004

Synthetic (Dronabinol)

2.5 mg –
10.0 mg

Capsule

Multiple Sclerosis

Numeric Rating Scale

0 – 10

2004

Synthetic (Dronabinol)

2.5 mg –
10.0 mg

Capsule

Multiple Sclerosis

Numeric Rating Scale

Route

Author Manuscript

21

Toth et al.

2012

Synthetic (Nabilone)

2.0 mg – 4.0
mg

Capsule

Diabetes

Numeric Rating Scale

0 – 10

22

Wade et al.

2003

Extract

2.5 mg
THC / 2.5
mg CBD

Oromucosal Spray

Various

Visual Analog Scale

0 – 100

Extract

2.5 mg THC

Oromucosal Spray

Various

Visual Analog Scale

0 – 100

Extract

2.5 mg CBD

Oromucosal Spray

Various

Visual Analog Scale

0 – 100

Whole Plant

7% THC

Humidified

Diabetes

Visual Analog Scale

0 – 10

Whole Plant

4% THC

Humidified

Diabetes

Visual Analog Scale

0 – 10

Whole Plant

1 % THC

Humidified

Diabetes

Visual Analog Scale

0 – 10

Whole Plant

9.4 % THC

Smoke

Neuropathic Pain

Numeric Rating Scale

0 – 10

Whole Plant

6.0 % THC

Smoke

Neuropathic Pain

Numeric Rating Scale

0 – 10

Whole Plant

2.5 % THC

Smoke

Neuropathic Pain

Numeric Rating Scale

0 – 10

Whole Plant

7.0 % THC

Smoke

Neuropathic Pain

Visual Analog Scale

0 – 100

Whole Plant

3.5 % THC

Smoke

Neuropathic Pain

Visual Analog Scale

0 – 100

23

24

25

Wallace et al.

Ware et al.

Wisley et al.

2015

2010

2008
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